Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Overview of the six original ACTIV-3/TICO trials. by Elizabeth S. Munroe (21568166)

Subjects:

Supplementary Material for: Priming short children with sex steroids prior to growth hormone testing decreases the frequency of divergent results by figshare admin karger (2628495)

Mean and standard error of pupil diameter in the dim states. by Tomoe Hayakawa (20978784)

Subjects:

Spontaneous oxycodone withdrawal initially flattens NREM power rhythms, decreases low frequency and increases high frequency power. by Michael Gulledge (20577135)

Subjects:

Mean ± SD of the different parameters relative to bipedal stance on soft support with the eyes open recorded in the Chewing and Hand Grip groups. by Cristina Dolciotti (16317330)

Subjects:

Repetitive stress induces a decrease in sound-evoked activity. by Ghattas Bisharat (20706928)

“…(d) Noise-evoked activity rates at different noise intensities for chronically tracked PV cells in baseline and repeated stress conditions (<i>N</i> = 5 mice, <i>n</i> = 31 neurons, mean ± SE). Activity rates decreased during repeated stress compared to baseline (2-way ANOVA, condition F = 49.6, <i>p</i> = 2.6 × 10⁻¹², condition: intensity interaction F = 1.94, <i>p</i> = 0.02, nested ANOVA (mouse nested within session), F = 56.5, <i>p</i> = 8.8 × 10⁻¹⁴, condition: intensity interaction F = 3.5, <i>p</i> = 3.5 × 10⁻⁰⁵). …”